The institutional hunt for returns brings green shoots February 25, 2013 BOTTOM LINE HEDGE funds didn’t always have an easy time of it in 2012 – witness the world’s biggest listed hedge fund Man Group, which parted company with its finance chief Kevin Hayes last June and announced in December its chief executive would step down in February 2013 following a year in which its plunging [...]
Deutsche Börse slaps down CME merger talks February 25, 2013 EXCHANGE rivals CME Group and Deutsche Börse saw a spike in trading yesterday after it emerged the two sides had met for talks about a possible merger. German exchange operator Deutsche Börse last night issued a statement denying it was in merger talks, shooting down rumours a deal could be on the cards after the [...]
Lazards is set to join Royal Mail advisers February 25, 2013 THE GOVERNMENT is in the process of appointing the independent investment bank Lazards to help advise it on the possible flotation or trade sale of the Royal Mail. Yesterday a spokesman for the Department for Business, Innovation and Skills said that Lazard was about to be appointed alongside UBS to give advice. Although the Royal [...]
Sinopec snaps up a stake in Chesapeake February 25, 2013 CHINA Petroleum & Chemical Corp (Sinopec) is set to buy half of Chesapeake Energy’s Mississippi Lime oil and gas properties in Oklahoma for $1.02bn (£672m) to increase its presence in the booming North American shale gas industry. Output from shale fields in the United States and Canada has jumped over the last three years due [...]
Nedbank uplift on retail gains February 25, 2013 SOUTH African bank Nedbank Group, part of London listed Old Mutual, yesterday said it boosted profits by nearly a fifth last year after strong revenue growth from its retail business. An additional 655,000 new retail customer helped increase the business’s diluted headline earnings per share, a key measure of profitability in South Africa, to jump [...]
Advisers Royalty Pharma February 25, 2013 HENRY GOSEBRUCH JP MORGAN CAZENOVE MANAGING DIRECTOR JP Morgan Cazenove is advising Royalty Pharma on its proposed purchase of Elan, led by Henry Gosebruch, who is a managing director in the firm’s mergers and acquisition group. Gosebruch’s focus is on the pharmaceutical and industrial sectors and he has worked on M&A transactions worth over $100bn [...]
Royalty makes $6.6bn bid for Irish firm Elan February 25, 2013 US investment firm Royalty Pharma yesterday made a $6.6bn (£4.35bn) approach to Irish drugmaker Elan, targeting royalty rights for multiple sclerosis treatment Tysabri worth hundreds of millions of dollars annually. But Elan described the informal approach as “highly opportunistic”, coming before shareholders could assess its plan to sell off Tysabri. Elan said earlier this month [...]
Reckitt loses fight to block generic drugs February 25, 2013 SHARES in Reckitt Benckiser closed three per cent lower yesterday after US authorities said they will allow rivals to produce generic versions of the firm’s heroin substitute. The consumer health goods company’s pharmaceuticals division makes most of its profit from Suboxone, a treatment containing buprenorphine that helps people addicted to opiates cope with ceasing to [...]
Barnes & Noble chair makes bid February 25, 2013 BARNES & Noble chairman Leonard Riggio yesterday offered to buy the US bookseller’s declining retail business, joining a growing list of executives lining up to buy the fading companies they founded. Barnes & Noble’s shares rose as much as 11 per cent in morning trading, valuing it at about $900m. The New York-based company’s retail business [...]
3i raises money for debt fund February 25, 2013 THE UK’s oldest private equity firm 3i Group yesterday said it had raised a $500m (£331m) collateralised debt obligation (CLO) fund, the latest push by the group into debt management. The company is currently in the midst of a strategic overhaul, led by chief executive Simon Borrows, in a bid to put more emphasis on [...]